| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Poncirin targets inflammatory pathways, inhibiting LPS-induced prostaglandin E2 and interleukin-6 (IL-6) production. It also inhibits iNOS expression. The compound prevents adipogenesis and enhances osteoblast differentiation in mesenchymal stem cells. It has shown significant inhibitory effects on the growth of human gastric cancer cells (SGC-791).
|
|---|---|
| ln Vitro |
In vitro, poncirin exhibits significant inhibitory effects on the growth of human gastric cancer cells SGC-791. It prevents adipogenesis and enhances osteoblast differentiation in mesenchymal stem cells. The compound inhibits LPS-induced prostaglandin E2 and IL-6 production. It also inhibits iNOS expression.
|
| ln Vivo |
Citrus aurantium (ip; 30 mg/kg) significantly decreased visceral pain caused by acetic acid and tonic pain induced by formalin in the complete Freund's adjuvant (CFA)-induced inflammatory pain model. pain-related behavior[1].
In vivo, poncirin significantly reduces mechanical hyperalgesia and allodynia in CFA-induced inflammatory pain models in mice. It increases bone mineral density and improves trabecular microarchitecture in GIO mice, reflecting increased bone formation and decreased bone resorption. The compound also exhibits larvicidal activity and repels insects. |
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, poncirin can be evaluated for its effects on inflammatory mediators. Cell-free assays can be performed to assess inhibition of iNOS or COX-2 activity. The compound is incubated with the enzyme and substrate, and activity is measured using colorimetric or fluorometric detection. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, poncirin is typically tested on macrophages or mesenchymal stem cells. Macrophages are treated with the compound and stimulated with LPS. Prostaglandin E2 and IL-6 production are measured by ELISA. Mesenchymal stem cells are treated with the compound and assessed for osteogenic differentiation using alkaline phosphatase staining and alizarin red staining. Cancer cell growth inhibition is assessed using MTT assays on gastric cancer cell lines.
|
| Animal Protocol |
For in vivo animal experiments, poncirin is typically administered orally to mouse models of inflammatory pain (CFA-induced) or osteoporosis (GIO mice). In pain models, mechanical hyperalgesia and allodynia are assessed using von Frey filaments. In osteoporosis models, bone mineral density and trabecular microarchitecture are assessed by micro-CT. Inflammatory markers are measured in serum or tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for poncirin are limited. As a flavonoid glycoside with a molecular weight of 594.56 g/mol, it is expected to have moderate oral bioavailability. The compound may undergo deglycosylation in the gastrointestinal tract. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for poncirin are limited. As a natural product isolate, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
(2S)-Hesperidin is a flavanone glycoside composed of a 4'-methoxy-5,7-dihydroxyflavanone linked to neohesperidin (α-L-rhamnosyl-(1→2)-β-D-glucopyranose) residue via a glycosidic bond. It was isolated from the fruit of Poncirus trifoliata and exhibits activity in inhibiting lipopolysaccharide (LPS)-induced prostaglandin E2 and interleukin-6 (IL-6) production. It is a plant metabolite. It is a monomethoxyflavanone, flavanone glycoside, disaccharide derivative, neohesperidin, and a member of the 4'-methoxyflavanone class of compounds. Functionally, it is related to 4'-methoxy-5,7-dihydroxyflavanone. Naringin has been reported in Poncirus trifoliata, Citrus medica, and other organisms with relevant data.
Poncirin is a research-use only compound and has not been approved for clinical applications. It is also known as Isosakuranetin-7-neohesperidoside. The compound is isolated from the fruits of Poncirus trifoliata. Its molecular weight is 594.56. It is available from various research chemical suppliers. |
| Molecular Formula |
C28H34O14
|
|---|---|
| Molecular Weight |
594.5612
|
| Exact Mass |
594.194
|
| Elemental Analysis |
C, 56.56; H, 5.76; O, 37.67
|
| CAS # |
14941-08-3
|
| PubChem CID |
442456
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
900.1±65.0 °C at 760 mmHg
|
| Melting Point |
210ºC
|
| Flash Point |
296.5±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.678
|
| Source |
Originated from plants: other families
|
| LogP |
3.39
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
42
|
| Complexity |
900
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
O([C@@]1([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])O[H])O[H])[C@@]1([H])[C@]([H])(OC2=C([H])C(=C3C(C([H])([H])C([H])(C4C([H])=C([H])C(=C([H])C=4[H])OC([H])([H])[H])OC3=C2[H])=O)O[H])O[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]1([H])O[H])O[H]
|
| InChi Key |
NLAWPKPYBMEWIR-SKYQDXIQSA-N
|
| InChi Code |
InChI=1S/C28H34O14/c1-11-21(32)23(34)25(36)27(38-11)42-26-24(35)22(33)19(10-29)41-28(26)39-14-7-15(30)20-16(31)9-17(40-18(20)8-14)12-3-5-13(37-2)6-4-12/h3-8,11,17,19,21-30,32-36H,9-10H2,1-2H3/t11-,17-,19+,21-,22+,23+,24-,25+,26+,27-,28+/m0/s1
|
| Chemical Name |
(2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
|
| Synonyms |
Poncirin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~168.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6819 mL | 8.4096 mL | 16.8192 mL | |
| 5 mM | 0.3364 mL | 1.6819 mL | 3.3638 mL | |
| 10 mM | 0.1682 mL | 0.8410 mL | 1.6819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
